Reply to Hagino et al.: ‘Importance of Upadacitinib dose escalation prior to switch to lebrikizumab’

Documenti analoghi

• Clearance of Darier disease lesions in a patient with concomitant atopic dermatitis treated with abrocitinib
  di: M. Bianco, et al.
  Pubblicazione: (2024)
• Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’
  di: Fabrizio Martora, et al.
  Pubblicazione: (2025)
• Effectiveness of dupilumab in tralokinumab‐resistant patients with atopic dermatitis: A real‐world experience from two referral centres
  di: Gianluca Tavoletti, et al.
  Pubblicazione: (2024)
• Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis
  di: Teppei Hagino, et al.
  Pubblicazione: (2025)
• Real world experience of switching from tralokinumab to lebrikizumab: Author's reply
  di: Teppei Hagino, et al.
  Pubblicazione: (2025)